First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)

Inclusion Criteria: * Subject is \> 18 years and \< 80 years of age * Written subject informed consent available prior to PCI * Subjects with stable or unstable angina pectoris or documented silent ischemia * Subject eligible for PCI * Subject acceptable candidate for coronary artery bypass surgery * Subjects with a maximum of two single lesions in two separate coronary arteries which have to be de novo lesions. * Reference vessel diameter between 2.2-3.8 mm by visual estimation * Target lesion length ≤ 21 mm by visual estimation * Target lesion stenosis by visual estimation, assisted by QCA / IVUS: \> 50% - \< 100% * Eligible for Dual Anti Platelet Therapy (DAPT) Exclusion Criteria: * Pregnant or breast-feeding females or females who intend to become pregnant during the time of the study * Evidence of myocardial infarction within 72 hours prior to index procedure * Subjects with a ≥2 fold CK level or in absence of CK a ≥3 fold CKMB level above the upper range limit within 24 hours prior to the procedure * Unprotected left main coronary artery disease * Three-vessel coronary artery disease at time of procedure * Thrombus in target vessel * Subject is currently participating in another study with an investigational device or an investigational drug and has not reached the primary endpoint yet * Planned interventional treatment of any non-target vessel within 30 days post-procedure * Subjects on dialysis * Planned intervention of the target vessel within 6-month after the index procedure * Ostial target lesion (within 5.0 mm of vessel origin) * Target lesion involves a side branch \>2.0 mm in diameter * Documented left ventricular ejection fraction (LVEF) ≤ 30% * Heavily calcified lesion * Target lesion is located in or supplied by an arterial or venous bypass graft * The target lesion requires treatment with a device other than the pre-dilatation balloon prior to scaffold placement (including but not limited to, rotational atherectomy, cutting balloon etc.) * Known allergies to: Acetylsalicylic Acid (ASA), Heparin, Contrast medium, Sirolimus, or similar drugs; or the scaffold material * Impaired renal function (serum creatinine \> 2.5 mg/dl or 221 mmol/l, determined within 72 hours prior to intervention) * Subject is receiving oral or intravenous immuno-suppressive therapy (e.g., inhaled steroids are not excluded) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, but not including diabetes mellitus) * Proximal or distal to the target lesion located stenosis that might require future revascularization or impede run off detected during diagnostic angiography * Life expectancy less than 1 year * Planned surgery or dental surgical procedure within 6 months after index procedure * In the investigators opinion subjects will not be able to comply with the follow-up requirements